Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Imbruvica 420mg tablets
0801050BSBBADAD
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
Imbruvica 560mg tablets
0801050BSBBAEAE
|
Imbruvica | Ibrutinib | Malignant Disease and Immunosuppression | No data available |
|
ImmuCyst 81mg instil vials
0802040X0BCAAAB
|
ImmuCyst | Bacillus calmette-guerin (B.C.G.) | Malignant Disease and Immunosuppression | No data available |
|
Immukin 100micrograms/0.5ml solution for injection vials
0802040Z0BBAAAA
|
Immukin | Interferon gamma | Malignant Disease and Immunosuppression | No data available |
|
Immunoprin 50mg tablets
0802010G0BEAAAE
|
Immunoprin | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Imnovid 1mg capsules
0802040AJBBAAAA
|
Imnovid | Pomalidomide | Malignant Disease and Immunosuppression | No data available |
|
Imnovid 2mg capsules
0802040AJBBABAB
|
Imnovid | Pomalidomide | Malignant Disease and Immunosuppression | No data available |
|
Imnovid 3mg capsules
0802040AJBBACAC
|
Imnovid | Pomalidomide | Malignant Disease and Immunosuppression | No data available |
|
Imnovid 4mg capsules
0802040AJBBADAD
|
Imnovid | Pomalidomide | Malignant Disease and Immunosuppression | No data available |
|
Imuran 50mg powder for solution for injection vials
0802010G0BCACAA
|
Imuran | Azathioprine | Malignant Disease and Immunosuppression | No data available |
|
Inlyta 1mg tablets
0801050BJBBAAAA
|
Inlyta | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Inlyta 3mg tablets
0801050BJBBADAD
|
Inlyta | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Inlyta 5mg tablets
0801050BJBBABAB
|
Inlyta | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Inlyta 7mg tablets
0801050BJBBACAC
|
Inlyta | Axitinib | Malignant Disease and Immunosuppression | No data available |
|
Inotuzumab ozogamicin 1mg inf vials
0801050CEAAAAAA
|
Inotuzumab | Inotuzumab | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 18million units/0.5ml inj pfs
0802040J0AABGBG
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 18million units/0.6ml inj cartridges
0802040J0AABFBF
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 3million units/0.5ml inj pfs
0802040J0AAAVAV
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 4.5million units/0.5ml inj pfs
0802040J0AAAWAW
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 6million units/0.5ml inj pfs
0802040J0AAAXAX
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2a 9million units/0.5ml inj pfs
0802040J0AAAYAY
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2b 10million unit inj vials
0802040J0AAAHAH
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2b 18million units/1.2ml inj pf dispos dev
0802040J0AABBBB
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2b 18million units/3ml inj vials
0802040J0AAAUAU
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Interferon alfa-2b 1million unit inj vials
0802040J0AAAKAK
|
Interferon A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.